Sarepta Therapeutics (SRPT) Misses Q4 EPS by 29c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
March 1, 2017 6:35 AM ESTRBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $91.00 (from $98.00) while maintaining a Outperform rating amid conservative guidance.
Analyst Simos Simeonidis commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT... More
